A Novel Combination of BroadBand Light (BBL® HEROTM) and Nonablative Fractionated 1,927nm (MOXITM) Laser for Addressing Solar Lentigines

Erin Hennessey
Abstract:Solar lentigo is a common condition that can affect people of all ages and ethnicities. The effectiveness of combining laser and light-based modalities for reducing solar lentigines was evaluated. Patients received treatment for facial solar lentigines with an advanced pulsed light device (BBL® HEROTM) followed by nonablative fractionated 1,927nm laser (MOXITM) in a single session. Nonmalignant solar lentigines were evaluated through assessment of photographs and VISIA scans taken before and after treatment. Nine patients aged 29 to 64 years were included in this report. Across all nine patients, there was a significant increase in percentile for brown spots on VISIA scans post-treatment. Follow-up time was variable; in one patient, a marked reduction in hyperpigmentation was observed almost 20 months post-treatment. The results presented in this report demonstrate that combining BBL HERO and MOXI is effective for reducing solar lentigines.
What problem does this paper attempt to address?